Wills Hughes-Wilson
Förmögenhet: 13 477 $ per 2026-08-31
Förmögenhet: 13 477 $ per 2026-08-31
Alexandra Hughes-Wilson is Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc since 2018.
Former roles include Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB from 2016 to 2018, Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd. Education includes a graduate degree from the University of Durham.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-02-01 | 252 375 ( 0,03 % ) | 13 477 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Företagsledare/Principal | 2018-03-01 |
| Företag | Position | Slut |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Offentlig kommunikationskontakt | 2018-01-01 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Företagsledare/Principal | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Direktör/Styrelseledamot | - |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
University of Durham
University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Health Technology |
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Mereo BioPharma Group Plc
Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån